| 10096 | 10096: A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) | Open |
| 10492 | 10492: Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer | Open |
| 1122GCC | Observational Study of hepatic metastasis of colorectal origin | Open |
| 1227GCC | Irreversible electroporation for locally advanced unresectable pancreatic cancer. | Open (affiliates only) |
| 1366GCC | A PROSPECTIVE STUDY OF NEOADJUVANT NON-STEROIDAL AROMATASE INHIBITORS IN POSTMENOPAUSAL WOMEN WITH OPERABLE HORMONE RECEPTOR-POSITIVE BREAST CANCER TO EVALUATE THE ANTI-PROLIFERATIVE RESPONSE IN OBESE AND OVERWEIGHT PATIENTS | Open |
| 1403GCC | An Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory Research | Open |
| 1495GCC | An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Thoracic Malignancies and Normal Subjects, to Be Used in Laboratory Research | Open |
| 1563GCC | Mitigation of radiation pneumonitis and fibrosis | Open (affiliates only) |
| 16115GCC | Integration of Cancer Health Activities into African American Churches | Open (affiliates only) |
| 1635GCC | Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereo-tactic Ablative Body Radiotherapy (SAbR)
| Open |
| 1697684-1 | 1697684-1: Project HEAL Community Health Advisor (CHA) Training | Open |
| 1718GCCC-S12 | 1718GCCC-S12: A Randomized Phase 2 Trial of 28 Day (Arm A) versus 14 Day (Arm B) Schedule of Venetoclax (Ven) + Azacitidine (Aza) in newly diagnosed acute myeloid leukemia (AML) patients >/= 60 years | Open |
| 1718GCCC-S17 | A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients >/= 60 years with NPM1 mutated AML or Mixed Lineage Leukemia (MLL) Gene Rearrangements | Open |
| 1775GCCC | DNA methylation at chromosome 8q24 and the risk of aggressive prostate cance | Open |
| 18106GCCC | 18106GCCC: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Open |
| 18149GCCC | 18149GCCC: Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis and Risk-Stratification of Prostate Cancer | Open |
| 1886GCC | Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine with Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer | Open |
| 19108GCCC | 19108GCCC: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Open |
| 1911GCCC | 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined with Gemcitabine for Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy | Open |
| 19125GCCC | 19125GCCC: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors | Open |
| 19140GCCC | PILOT STUDY OF LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION THERAPY FOR RECURRENT HIGH GRADE GLIOMAS | Open |
| 1926GCCC | A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast S-PBI for Early Stage Breast Cancer | Open |
| 1944GCCC | A Randomized Phase III Trial of Two Standard Dose Fractionation Regimens for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer
| Open |
| 1946GCCC | A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients with Persistent, Relapsed or Refractory Acute Myeloid Leukemia | Open |
| 1949GCCC | 1949GCCC: GP-88 Levels in Metastatic Breast Cancer: A Prospective Blood Sampling trial | Open |
| 1950GCCC | 1950GCCC: First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND # Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer (NSCLCA) and advanced Mesothelioma | Open |
| 1971456-1 | 1971456-1: UMGCCC Community Research Forums | Open |
| 1973296-9 | 1973296-9: Multi-level drivers of cancer disparities impacting African Americans | Open |
| 1974GCCC | 1974GCCC: Correlation of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging and Tumor Histopathology in Patients with Infiltrating Gliomas | Open |
| 20138GCC | LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY HYPOFRACTIONATED RADIATION THERAPY FOR TREATMENT OF NEWLY DIAGNOSED HIGH-GRADE GLIOMAS | Open |
| 20141GCCC | The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer | Open |
| 2031GCCC | 2031GCCC: Polyploid giant cancer cells actuate prostate cancer tumor resistance and lethal phenotype | Open |
| 2032GCC | Feasibility of Strength Training with Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer | Open |
| 2048GCC | A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED ACCELERATED PELVIC NODAL RADIOTHERAPY DELIVERED WITH A SIMULTANEOUSLY INTEGRATED PROSTATE BOOST FOR PATIENTS WITH LOCALIZED, INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
| Open |
| 2073GCC | THE UPPROACH APPROACH: A PHASE 2 STUDY OF UPFRONT INTENSITY MODULATED PROTON BEAM THERAPY (IMPT) AND CONCURRENT CHEMOTHERAPY FOR POST-OPERATIVE TREATMENT IN LOCO-REGIONALLY ADVANCED ENDOMETRIAL CANCER
| Open |
| 2078GCCC | 2078GCCC: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) | Open |
| 2083GCCC | 2083GCCC: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma | Open |
| 2092GCCC | 2092GCCC: A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma | Open |
| 2102GCCC | 2102GCCC: A six-patient case series of patients with therapy-related acute lymphoblastic leukemia following multiple myeloma | Open |
| 21112GCCC | 21112GCCC:Open-Label, Multicenter, Phase 1 Study to Assess the Safety of
P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple
Myeloma (MM) PROTOCOL NUMBER P-BCMA-ALLO1-001 | Open |
| 21136GCC | Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial
| Open |
| 21137GCCC | 21137GCCC: The effects of exercise and nutrition interventions on chemotherapy-induced peripheral neuropathy and interoceptive brain circuitry | Open |
| 2117GCCC | A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-04) | Open |
| 2148GCCC | 2148GCCC: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
| Open |
| 2162GCCC | 2162GCCC: Project HEAL Community Health Advisor (CHA) Training ( HP-00095931) | Open |
| 2180GCCC | 2180GCCC: Outcomes in acute myeloid leukemia treated with gemtuzumab ozogamicin versus anthracycline-based regimens: A multi-institutional review | Open |
| 2187GCCC | 2187GCCC: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Open |
| 2195GCCC | PHASE 1/2 STUDY OF REGN4336 (A PSMAXCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Open |
| 2198GCCC | 2198GCCC: A Phase 1/2 open-label, biomarker-defined cohort trial to evaluate the safety, determine the recommended combination dosing, and assess early antitumor activity of tipifarnib and alpelisib for the treatment of adult participants who have HRASoverexpressing and/or PIK3CA-mutated and/or -amplified recurrent/metastatic head and neck squamous cell carcinoma (the Kurrent trial) KO-TIP-013 | Open |
| 2201GCCC | 2201GCCC:Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions | Open |
| 2202GCCC | 2202GCC: Adjuvant Therapy for Invasive IPMN (HP-00098809) | Open |
| 2203GCCC | 2203GCCC: The Fatigue REDuction After cancer (FREDA) trial: A phase II randomized controlled trial evaluating the effects of healthy lifestyle behaviors on circadian rhythm and fatigue among cancer survivors | Open |
| 2208GCCC | 2208GCCC:A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) | Open |
| 22103GCCC | 22103GCCC: Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma | Open |
| 22104GCCC | 22104GCCC: A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma | Open |
| 22115GCCC | The safety and efficacy of cyclin-dependent kinases 4/6 inhibitors in older adults with breast cancer | Open |
| 22121GCCC | 22121GCCC: A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Open |
| 22124GCCC | 22124GCCC: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy | Open |
| 22125GCCC | 22125GCCC:Outcomes of Patients with Invasive Breast Cancer (Hormone Positive, HER-2 Positive, Triple Negative) in an Urban, Single Center Institution (HP-00102963) | Open |
| 22126GCCC | 22126GCCC: An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors | Open |
| 22127GCCC | 22127GCCC: A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | Open |
| 22128GCCC | 22128GCCC: Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE) | Open |
| 2212GCCC | GCC 2212- Protons for Rectal Cancer after Prior Prostate Cancer | Open (affiliates only) |
| 22130GCCC | 22130GCCC: An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23) | Open |
| 22132GCCC | 22132GCCC: A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma | Open |
| 2214GCCC | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Open |
| 2218GCCC | 2218GCCC:A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | Open |
| 2221GCCC | A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193
alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors | Open |
| 2227GCCC | 2227GCCC: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS
WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Open |
| 2228GCCC | 2228GCCC:Effects of exercise during platinum chemotherapy on neuropathy: examining the interoceptive brain system and inflammation (HP-00100000) | Open |
| 2230GCCC | BT012:A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastases of non-small cell lung cancer (NSCLC) origin | Open |
| 2236GCCC | 2236GCCC: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma | Open |
| 2242GCCC | Hybrid Virtual MRI/CBCT for Image Guidance in Liver Radiation Therapy | Open |
| 2246GCCC | 2246GCCC:Prognostic factors, treatment patterns and outcomes for multiple myeloma (HP-00100621) | Open |
| 2250GCCC | 2250GCCC:A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate
Model 4000 using Microbubble Resonators to Temporarily Mediate
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects
with Glioblastoma Brain Tumors (BT015) | Open |
| 2252GCCC | 2252GCCC:Predictors of time to relapse after transplant in multiple myeloma ( HP-00101322) | Open |
| 2253GCCC | 2253GCCC: A Phase 1 open-label, dose-finding multi-center trial of [177Lu]Ludotadipep in metastatic castration-resistant prostate cancer patients, followed by an open-label, repeat dose, multi-center Phase 2a trial to assess safety and efficacy | Open |
| 2254GCCC | A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies | Open |
| 2259GCCC | 2259GCCC: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | Open |
| 2261GCCC | 2261GCCC: A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC 9) | Open |
| 2267GCCC | 2267GCCC:Integrated Model for the Prevention of Anal Cancer using screen and Treat for HSIL (IMPACT) (HP-00101383) | Open |
| 2272GCCC | A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | Open |
| 2273GCCC | 2273GCCC:An adaptive, regimen finding, safety and tolerability study of TCD601 (siplizumab), a human anti-CD2 antibody, combined with donor bone marrow cell infusion and non-myeloablative conditioning, for tolerance induction in de novo living donor renal transplantation (PANORAMA) (HP-00100010) | Open |
| 2274GCCC | 2274GCCC: A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA) | Open |
| 2276GCCC | 2276GCCC:comparison of core cell blocks obtained via different modalities (HP-00101323) | Open (affiliates only) |
| 2277GCCC | 2277GCCC:Financial resources and healthcare resource utilization (HP-00100497) | Open |
| 2278GCCC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease | Open |
| 2280GCCC | 2280GCCC:Leveraging Technology to Address POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC-II): A Phase II Survivorship Care Plan Randomized Controlled Trial (HP-00100473) | Open |
| 2282GCCC | 2282GCCC: A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT) | Open |
| 2284GCCC | 2284GCCC:A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination
with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial
Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible
for or Refusing Platinum-Based Neoadjuvant Chemotherapy
SunRISe-4 (HP-00101541)
| Open |
| 2285GCCC | 2285GCCC:MK -3475 Retrospective Study/ A non-interventional retrospective real-world study to assess treatment patterns, surrogate endpoints & overall survival in muscle invasive bladder cancer (MIBC) | Open |
| 2286GCCC | 2286GCCC: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies | Open |
| 2290GCCC | 2290GCCC: A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Open |
| 2293GCCC | 2293GCCC: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02) | Open |
| 2298GCCC | 2298GCCC:A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study
of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given
Concurrently with Transarterial Chemoembolization (TACE) Compared to
TACE Alone in Patients with Locoregional Hepatocellular Carcinoma
(EMERALD-3) | Open |
| 2304GCCC | A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | Open |
| 2307GCCC | 2307GCCC: Vaccine Acceptance and Chatbox | Open |
| 23100GCC | A randomized trial of high-risk Metachronous Oligometastatic prostate cancer with High-risk mutations treated with metastasis directed therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS) | Open |
| 23113GCCC | 23113GCCC:A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis | Open |
| 23115GCCC | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | Not Open |
| 23116GCC | Retrospective review of the impact of genomic alterations on breast cancer patients undergoing therapeutic intervention | Open |
| 2311GCCC | 2311GCCC: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma | Open |
| 2320GCCC | 2320GCCC: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel | Open |
| 2325GCCC | 2325GCCC: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | Open |
| 2327GCCC | 2327GCCC: HIV lymphoma/Analysis of clinical presentations, outcomes, and toxicities in patients with HIV lymphoma treated at the University of Maryland (HP-00105229) | Open |
| 2331GCCC-EA | 2331GCCC: spIND Treatment Plan of topical Ruxolitinib for MAE | Open |
| 2332GCCC | 2332GCCC: A Multicenter Open label Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only Including L861Q G719X and/or S768I) | Open |
| 2333GCCC | 2333GCCC: A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting (20220083) | Open |
| 2335GCCC | 2335GCCC: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Open |
| 2339GCCC | 2339GCCC: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors | Open |
| 2342GCCC | 2342GCCC: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | Open |
| 2351GCCC | 2351GCCC: A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination with Pembrolizumab in Patients with Solid Tumors | Open |
| 2355GCCC | 2355GCCC: A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors | Open |
| 2358GCCC | 2358GCCC: A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | Open |
| 2361GCCC | 2361GCCC: Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine vs. placebo in patients with residual disease post-neoadjuvant chemotherapy | Open |
| 2363GCCC | 2363GCCC:Plasma Biomarkers for Lung Cancer Diagnosis (HP-00106262) | Open |
| 2365GCCC | 2365GCCC: A Phase 3 Randomized Clinical Study of MK-4280A (coformulated
favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice
Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
(KEYFORM-008)
| Open |
| 2367GCCC | 2367GCCC: A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma (20210031) | Open |
| 2373GCCC | 2373GCCC:Diaphragm structure and function in childhood cancer survivors (HP-00106329) | Open |
| 2374GCCC | 2374GCCC:The Impact of the COVID-19 pandemic on Healthcare Utilization (HP-00104540) | Open |
| 2379GCC | IImplications of Religious Beliefs, Mistrust and Other Psychosocial, Demographic and Economic Variables Influencing a Patient’s Decision on Enrolling in Radiation-Specific Cancer Trials | Open |
| 2380GCC | A Single Arm phase I-II trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs based on Residual Circulating Tumor DNA (ctDNA) Levels (SAVAL) | Open |
| 2382GCCC | 2382GCCC: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia | Open |
| 2383GCCC | 2383GCCC:ADRIAN: Towards understanding of ADT treatment and dietary patterns,
circadian rhythm, physiological responsiveness, and frailty (HP-00106546) | Open |
| 2387GCCC | 2387GCCC: PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness | Open |
| 2395GCCC | 2395GCCC:Examining vestibular, audiometric and balance function in childhood cancer(HP-00107346) | Open |
| 2399GCCC | 2399GCCC: The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects with Relapsed or Refractory CD19-Positive B-Cell Malignancies | Not Open |
| A011202 | A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH
NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY | Open (affiliates only) |
| A011401 | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer | Open (affiliates only) |
| A011502 | Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy | Open (affiliates only) |
| A011801 | Alliance A011801, The CompassHER2 trials (Comprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib (NCT #0445-7596) | Open |
| A021502 | A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair | Open (affiliates only) |
| A021806 | A021806: A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER | Open |
| A031803 | A031803: Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | Open |
| A071401 | PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS
WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS | Open |
| A081801 | A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO | Open (affiliates only) |
| A151804 | A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events | Open (affiliates only) |
| A212102 | A212102:Blinded Reference Set for Multicancer Early Detection Blood Tests | Open |
| A221805 | DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY | Open |
| A222004 | A222004:A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA | Open |
| AALL1731 | AALL1731: A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) | Open |
| AALL1732 | AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy | Open |
| AB-10-8001 | Ausperbio/AB-10-8001:A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF AHB-137 WITH SINGLE ASCENDING DOSES AND MULTIPLE DOSES IN HEALTHY VOLUNTEERS AND INITIAL EFFICACY IN CHRONIC HEPATITIS B PATIENTS (AB-10-8001) | Open |
| AM0010-301 | A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First- Line Gemcitabine Containing Regimen | Open |
| ANHL1931 | A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with
Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell
Lymphoma | Open |
| APEC14B1 | THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY | Open |
| APEC1621SC | APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol | Open |
| CCTGMA39 | TAILOR RT: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Open |
| EA1151 | EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST) | Open (affiliates only) |
| EA2185 | EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs | Open (affiliates only) |
| EA3132 | Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing | Open (affiliates only) |
| EA3161 | EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally
Advanced, Intermediate Risk HPV Positive OPSCC
| Open |
| EA3191 | EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features | Open |
| EA3202 | EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers | Open |
| EA5181 | EA5181: Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC | Open |
| EA8191 | hase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence(INDICATE) | Open |
| GO42784 | GO42784: A PHASE III, RANDOMIZED,OPEN-LABEL, MULTICENTER STUDY EVALUATING THE
EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER | Open |
| HM-TRIA-201 | HP-00092935:A phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH | Open |
| HP-00089292 | HP-00089292: microRNAs as biomarkers for cervical cancer screening (MBC) Study | Open |
| MTG-015 | MTG-015: Tissue and Bodily Fluids: Discovery and evaluation of biomarkers for the diagnosis and treatment of disease | Open (affiliates only) |
| N1048 | PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | Open (affiliates only) |
| NCT03856437 | NCT03856437:A Message Framing Intervention for Increasing Parental Acceptance of Human
Papillomavirus Vaccination | Open (affiliates only) |
| NCT05086354 | NCT05086354: Examining a Training Program for Acute Lymphoblastic Leukemia Childhood Cancer Survivors (JUMP) | Open |
| NCT05181072 | Assessing the Effectiveness of Virtual versus In-Person Peer-Motivation Smoking Cessation
Interventions | Open |
| NHLBI-MDS | A prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History | Open (affiliates only) |
| NRG-BN011 | A Phase III Trial of Lomustine-Temozolomide Combination
Therapy Versus Standard Temozolomide in Patients with Methylated MGMT
Promoter Glioblastoma | Open |
| NRG-BN012 | A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases | Open |
| NRG-CC009 | Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
| Open |
| NRG-GI003 | A PHASE III RANDOMIZED TRIAL OF PROTONS VERSUS PHOTONS
FOR HEPATOCELLULAR CARCINOMA | Open |
| NRG-GI005 | NRG-GI005:Phase II/III study of Circulating tumor DNA as a predictive Biomarker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) (NCT #04068103) | Open (affiliates only) |
| NRG-GI008 | NRG-GI008:Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) | Open |
| NRG-GY005 | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | Open |
| NRG-GY012 | A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer | Open |
| NRG-LU007 | Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial | Open |
| NSABP-C-14 | NSABP-C-14:CORRECT- MRD II: Second Colorectal cancer clinical validation study to predict Recurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease | Open |
| PATH/HITCH | PATH/HITCH: Prospective Analysis of Transgender Individuals At-Risk and Living with HIV to understand the impact of Integrating HIV Treatment and Prevention into Transgender Care Utilizing Hormone Therapy (HP-00090161) | Open |
| S1501 | Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer | Open (affiliates only) |
| S1706 | A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer | Open |
| S1826 | A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA | Open (affiliates only) |
| S1914 | S1914:A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC | Open |
| S2010 | S2010:A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN) | Open (affiliates only) |
| S2206 | S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer | Open (affiliates only) |
| TOL2506A | TOL2506A:A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | Open |